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introduction: Mixed adeno-neuroendocrine carcinoma (MANEC) is a rare pathological 
diagnosis recently defined by the World Health Organization (WHO) in 2010. Prior to the 
definition by the WHO, tumors with both adenocarcinoma and neuroendocrine compo-
nents were given multiple pathological designations making it difficult to characterize the 
disease. The aim of our study is to better characterize MANEC to better understand its 
natural history to influence patient care and positively impact outcomes.
Materials and methods: The surveillance, epidemiology, and end results program 
database was queried for all patients aged 18 years or older between 1973 and 2012 
who had the diagnosis composite carcinoid (n =  249) of the appendix. Composite 
carcinoid tumors refer to tumors that have both adenocarcinoma and carcinoid tumor 
components present, consistent with that pathological diagnosis MANEC. For compari-
son, the database was also queried for carcinoid tumor of the appendix (n = 950), signet 
ring cell carcinoma of the appendix (n = 579), and goblet cell carcinoid (GCC) tumors of 
the appendix (n = 944). The data were retrospectively reviewed, and clinicopathological 
characteristics, treatment regimens, and survival data were obtained.
results: The median age of diagnosis of MANEC tumors was 58 years of age. Eighty 
percent of patients were White, and 49% were female. Fifty-four percent of patients 
underwent hemicolectomy and 31% had partial/subtotal colectomy as their surgical 
management. Median overall survival for MANEC was 6.5 years (95% CI 4.5–9.7), which 
was statistically significantly shorter (p <  0.0001) in comparison to 13.8  years (95% 
CI 12.1–16.5) for GCC, 2.1 years (95% CI 1.8–2.3) for signet ring cell carcinoma, and 
39.4 years (95% CI 37.1–NA) for carcinoid tumors.
Discussion: MANEC is a more aggressive clinical entity than both GCC of the appendix 
and carcinoid tumors of the appendix. Based on these findings, patients with MANEC 
tumors should undergo aggressive multidisciplinary cancer management.
Keywords: mixed adeno-neuroendocrine carcinoma, colonic neoplasms, appendiceal neoplasm, seer
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inTrODUcTiOn
Mixed adeno-neuroendocrine carcinoma (MANEC) is a rare 
pathological diagnosis recently defined by the World Health 
Organization (WHO) in 2010 (1). Tumors are given the designa-
tion MANEC when they have both epithelial and neuroendocrine 
components, and each represents at least 30% of the tumor (1). 
Additionally, two out of the three commonly used pathological 
neuroendocrine markers, synaptophysin, chromogranin, and 
CD56, must be present (1, 2). Data are lacking regarding staging 
and prognosis for this histological subtype.
Prior to the definition by the WHO, tumors with both 
epithelial and neuroendocrine components were given multiple 
pathological designations making it difficult to characterize 
the disease. Designations included but are not limited to, 
goblet cell carcinoid (GCC), adenocarcinoma ex GCC, com-
posite tumors, adenocarcinoid, collision tumors, and mixed 
endocrine– exocrine tumors (3–6). MANEC tumors have been 
found in the colon, rectum, appendix, stomach, and biliary tract, 
but reports primarily consist of case reports and small series 
(7–10). In  particular, primary tumors of the appendix are very 
rare and only found in approximately 0.9–1.4% of appendectomy 
specimens (11, 12). The histological subtype of the appendiceal 
tumor plays a significant role in the biological behavior of the 
tumor and the overall survival (OS). The frequency of different 
histological subtypes varies, 11–20% are carcinoid, 14–19% 
GCC, 25–27% adenocarcinoma, 37% mucinous adenocarci-
noma, and 4–6% signet ring cell carcinoma (13, 14). Due to the 
recent pathological designation by the WHO, it is likely that 
some of the subtypes presented above may include MANEC 
tumors. Therefore, the true incidence and biological behavior 
of the disease are largely unknown.
The majority of published literature about MANEC includes 
small case series and case reports; therefore, there is limited data 
regarding the clinical behavior of MANEC tumors. It is currently 
unclear whether MANEC is more biologically similar to its car-
cinoid/neuroendocrine or adenocarcinoma components (10, 15, 
16). Classification as appendiceal carcinoid or neuroendocrine 
tumor is associated with a more indolent biology and often 
requiring only appendectomy for treatment. On the other hand, 
classification as an adenocarcinoma often requires more aggres-
sive management with consideration for right hemicolectomy 
and systemic therapy depending on pathological disease staging. 
With recent recognition of MANEC as a distinct clinical entity, 
understanding the natural history and prognosis of MANEC is 
necessary to ensure proper and optimal management of these 
patients.
The aim of our study is to use the national surveillance, epide-
miology, and end results (SEER) database to better characterize 
MANEC to understand the clinical behavior and biology of this 
disease.
MaTerials anD MeThODs
Protocol approval was obtained from the Ohio State University 
(OSU) Wexner Medical Center Institutional Review Board to 
query the SEER Program of the National Cancer Institute (NCI) 
database. The SEER database contains cancer incidence and 
survival data for population-based cancer registries that cover 
approximately 30% of the United States population (17). Data are 
included for patients aged 18 years or older between 1973 and 2012 
(18). The database was queried using International Classification of 
Diseases for Oncology 3 (ICD-O-3) histology and behavior codes. 
The histological subtypes were classified as follows: composite 
carcinoid of the colon and rectum (8244/3), GCC of the appendix 
(8243), signet ring cell carcinoma of the appendix (8490), and car-
cinoid/neuroendocrine tumor of the appendix (8240). Composite 
carcinoid tumors refer to tumors that have both adenocarcinoma 
and carcinoid tumor components present where at least 30% of 
each subtype is present in the tumor, consistent with WHO clas-
sification for MANEC. As MANEC is a fairly new pathological 
designation, the SEER database has not been updated with this 
designation, but the definition of composite carcinoid is consist-
ent with MANEC, so it was used for the purposes of this study.
There were 431 patients identified with composite carcinoid of 
the colon and rectum (SEER MANEC equivalent), 950 carcinoid 
tumor of the appendix, 579 signet ring cell carcinoma of the 
appendix, and 944 GCC tumors of the appendix. The majority of 
MANEC tumors arose in the appendix (58%) with the remaining 
tumors arising in the cecum (15%), rectum (9%), descending 
colon (1%), sigmoid colon (4%), and ascending colon (4%). 
With the non-MANEC histologies being appendiceal only, the 
appendiceal MANEC (n = 249) were used for clinicopathological 
and survival comparisons.
The data were retrospectively reviewed, and demographics, 
clinicopathological characteristics, treatment regimens, and 
survival data were obtained.
statistical analysis
Demographics and clinical characteristics were summarized 
using descriptive statistics. Chi-square test was used to compare 
categorical variables and Kruskal–Wallis test was used to compare 
age and tumor size. OS was calculated from the date of diagnosis 
to death from any cause. Survival curves were estimated using 
the method of Kaplan–Meier. Survival curves were compared 
between groups using log-rank test. Bonferroni method was used 
to adjust for multiple comparisons. In order to control for the 
effect of age and stage, Cox proportional regression model was 
also used to examine the association between OS and the disease 
groups. Estimated median with 95% confidence intervals were 
provided. p Values <0.05 were considered statistically significant. 
All statistical analyses were conducted using SAS version 9.3 (SAS 
Institute, Cary, NC, USA).
resUlTs
The demographic data of the patients with MANEC, GCC, signet 
ring carcinoma, and carcinoid/neuroendocrine carcinoma that 
were identified were compared and summarized in Table  1. 
The median age of diagnosis of MANEC (composite carcinoid) 
tumors was 58  years of age, which was comparable to signet 
ring carcinoma (median 58 years) and GCC (median 56 years), 
but was significantly older in comparison to carcinoid (median 
40 years) (p < 0.0001). Eighty percent of MANEC patients were 
TaBle 2 | clinicopathological characteristics.
Manec (n = 249) signet ring (n = 579) gcc (n = 944) carcinoid (n = 950) p-Value
Grade, no. (%) <0.0001*
I. Well differentiated 22 (9) 18 (1) 70 (7) 174 (18)
II. Moderately differentiated 13 (12) 36 (6) 61 (7) 40 (4)
III. Poorly differentiated 59 (24) 297 (51) 47 (5) 7 (<1)
IV. Undifferentiated, anaplastic 9 (4) 30 (5) 2 (<1) 4 (<1)
Unknown 128 (51) 208 (36) 764 (81) 725 (76)
Stage, no. (%) <0.0001*
I 19 (8) 27 (5) 105 (22) 212 (52)
II 107 (45) 106 (20) 302 (63) 73 (18)
III 39 (16) 90 (17) 34 (7) 84 (20)
IV 73 (30) 317 (59) 42 (9) 31 (8)
Median overall survival (years) 6.5 2.1 13.8 39.4 <0.0001*
*Statistical significant p-value <0.05.
TaBle 1 | Patient demographics.
Manec (n = 249) signet ring (n = 579) gcc (n = 944) carcinoid (n = 950) p-Value
Age, median (range) 58 (10–86) 58 (25–90) 56 (18–99) 40 (9–89) <0.0001*
Gender, no. (%) <0.0001*
Female 122 (49) 346 (60) 460 (49) 630 (66)
Male 127 (51) 233 (40) 484 (51) 320 (34)
Race, no. (%) <0.0001*
White 199 (80) 456 (79) 790 (84) 767 (81)
Black 21 (8) 52 (9) 78 (8) 67 (7)
Asian/Pacific Islander 4 (2) 30 (5) 32 (3) 23 (2)
Hispanic 22 (9) 38 (7) 37 (4) 76 (8)
American Indian/Alaska Native 1 (<1) 2 (<1) 1 (<1) 3 (<1)
Unknown 2 (<1) 1 (<1) 6 (<1) 14 (2)
*Statistical significant p-value <0.05.
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White, which was comparable to GCC (84%), signet ring cell 
carcinoma (79%), and carcinoid tumors (81%). There was a fairly 
equal gender distribution with 49% females and 51% males.
The clinicopathological characteristics of the different histolo-
gies were compared, as illustrated in Table 2. Pathologically, 24% 
of MANEC tumors were poorly differentiated, which was a statis-
tically significant higher proportion in comparison to GCC (5%) 
(p < 0.0001). Additionally, MANEC tumors were more likely to 
have distant spread at the time of diagnosis (31%), in comparison 
to GCC (9%) and carcinoid (9%) (p < 0.0001). Notably, 59% of 
signet ring cell carcinoma present with distant disease.
For MANEC patients, 8% were diagnosed with Stage I disease, 
45% with Stage II, 16% with Stage III, and 30% with Stage IV, which 
was significant in comparison to GCC, signet ring, and carcinoid 
tumors (p < 0.0001) (Table 2). In examining stage IV disease at 
presentation, MANEC presented with 30% compared with 59, 9, 
and 8% for signet ring, GCC, and carcinoid, respectively.
Median OS for MANEC was 6.5  years (95% CI 4.5–9.7), 
which was statistically significantly shorter (p  <  0.0001) in 
comparison to both 13.8 years (95% CI 12.1–16.5) for GCC and 
39.4  years (95% CI 37.1–NA) for carcinoid tumors but longer 
in comparison to 2  years (95% CI 1.8–2.3) for signet ring cell 
carcinoma (Figure 1). Subgroup analysis was performed for all 
patients with “Colon excluding rectum” as their cause of death, 
to account for disease-specific survival. Median disease-specific 
survival for MANEC was 1.5 years (95% CI 1.1–1.8), which was 
similar to signet ring 1.3 years (95% CI 1.2–1.5) and carcinoid 
1.8 years (95% CI 0.8–3.8), but statistically significantly shorter 
in comparison to 2.3 years (95% CI 1.7–2.8, p = 0.007) for GCC. 
Importantly, the OS for Stage IV MANEC was 1.5  years (95% 
CI 1.2–1.9), which was shorter than carcinoid (6.3 years, 95% CI 
1.5–NA, p = 0.005). OS for Stage IV MANEC was similar to that 
of signet ring (1.3 years, 95% CI 1.2–1.6) and GCC (1.9 years, 95% 
CI 1.3–3.2) (Figure  2). Over time, the classification of tumors 
with both neuroendocrine and adenocarcinoma has changed. 
MANEC was recognized as distinct entity by SEER in 2007 and 
then was further defined by the WHO in 2010. OS for patients 
diagnosed in or after 2007 for MANEC was not reached (NR) 
(95% CI 3.7–NR) and for signet ring cell carcinoma was 2.2 years 
(95% CI 1.8–2.7). For GCC and carcinoid tumor, median OS was 
NR. As the distribution of stage varies among tumor types and 
there are differing ages at diagnosis, cox proportional regression 
model was used to assess association between OS and cancer 
type, controlling for age at diagnosis and stage. There is a statisti-
cally significant increased hazard from MANEC in comparison 
to carcinoid tumor [hazard ratio (HR) 3.3 (95% CI 2.8–4.9)] 
(p < 0.0006). There is no significant difference in hazard between 
GCC and MANEC [HR 0.829 (95% CI 0.6–1.1) (p = 1)]. Fifty-four 
percent of MANEC patients underwent hemicolectomy, and 31% 
had partial/subtotal colectomy as their surgical management.
FigUre 2 | Kaplan–Meier survival curve for patients with stage iV 
only carcinoid tumors, gcc, Manec, and signet ring cell carcinoma.
FigUre 1 | Kaplan–Meier survival curve for patients with carcinoid 
tumors, gcc, Manec, and signet ring cell carcinoma.
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DiscUssiOn
Carcinoid/neuroendocrine tumors are typically considered to 
be less aggressive tumors as 1- and 5-year survival rates have 
been reported to be as high as 98.1 and 88.7%, respectively. Some 
studies have shown 10-year survival rates as high as 91% even 
in patients with positive lymph nodes (19–21). Consistent with 
our findings, GCCs of the appendix have been regarded as more 
aggressive than carcinoid/neuroendocrine tumors with regard 
to the extent of disease spread at diagnosis and the number of 
cases of lymph node involvement (14). Signet ring cell carcinoma 
represents the most aggressive histology with 76% of patients 
presenting with metastatic disease (14).
Due to the recent pathological designation of MANEC, 
there is little long-term outcome data and literature to guide 
clinical management. Prior to its definition as a distinct clinical 
entity, MANEC was often treated similar to their less aggressive 
counterparts, GCCs and carcinoid/neuroendocrine tumors of 
the appendix. This analysis of the SEER database represents the 
largest retrospective analysis of MANEC patients. Based on our 
analysis of the SEER database, MANEC appears to represent a 
more aggressive histology than both carcinoid tumors and GCC. 
We found OS for MANEC of 6.5 years (95% CI 4.5–9.7) to be 
significantly shorter than that of both carcinoid tumors and GCC. 
Additionally, a large proportion of patients were diagnosed with 
Stage IV disease (30%) in comparison to only 8% of carcinoid 
tumors and 9% of GCC. Furthermore, carcinoid tumors have 
a significantly lower age at diagnoses of 40, in comparison to 
58 for MANEC and signet ring and 56 for GCC. The lower age 
at diagnosis and variations in proportions of stage may act as 
confounders in our survival analysis. Therefore, cox proportional 
regression models were performed and when controlling for both 
the age at diagnosis and the variations in stage across tumor types, 
there is 2.3 times higher hazard of dying from MANEC in com-
parison to carcinoid and hazard is similar to GCC. Importantly, 
the OS for stage IV only disease of 1.5 years (95% CI 1.2–1.9) was 
also significantly shorter than carcinoid and more comparable 
to signet ring cell tumors and GCC, suggesting that, in fact, 
MANEC is an aggressive clinical entity. Importantly, over time 
as MANEC became recognized as a distinct clinical entity by the 
WHO in 2010 and SEER in 2007, treatment of mixed histology 
tumors may have evolved. Our study spans a wide time frame 
from 1973 to 2012, and OS for patients diagnosed after 2007 
MANEC is NR (95% CI 3.7–NR) and for signet ring 2.2 years 
(95% CI 1.8–2.7). The majority of patients in this 6-year time 
frame for GCC, carcinoid, and the MANEC group are still alive, 
and therefore median OS is NR. This fact limits our ability to 
account for evolving therapies over time. Despite these limita-
tions, these findings suggest that MANEC is a more aggressive 
entity that carcinoid.
These findings are consistent with our previously published 
experience with MANEC tumors (n = 46) at a single institution 
(22). We found that OS was 4.1  years, which was statistically 
significantly shorter in comparison to 13.4  years for carcinoid 
tumor, 15.4 years for GCC, and longer than 2.2 years for signet 
ring carcinoma (p < 0.05). The OS for stage IV appendiceal only 
MANEC was also statistically significantly shorter than carcinoid 
tumor (p < 0.05). Differences in OS between this study and our 
previous review may be related to the fact that this study includes 
appendiceal only tumors, and the previous data include appen-
diceal, small bowel, and colonic tumors. Based on that study, it 
is recommended that patients with MANEC undergo multidis-
ciplinary oncologic management, which may include systemic 
therapy and right hemicolectomy with possible cytoreductive 
surgery with HIPEC in patients with peritoneal metastases.
In contrast to our findings, La Rosa et al. found that there was 
not a statistically significant difference in OS between MANEC 
and carcinoid tumors. This finding may be explained by the 
low sample size of 12 in their study in comparison to this larger 
sample size. Additionally, there were differences in the distribu-
tion of stage at diagnosis between La Rosa et al. and our study. 
They found 83 and 17% of patients presented with Stage III and 
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Stage IV disease, respectively, whereas we found 16 and 30% of 
patients presented Stage III and Stage IV disease, respectively. 
Due to limitations of the SEER database, we were unable to assess 
immunohistochemical profiles or morphologic profiles. However, 
La Rosa et  al. did show that 92% of MANECs had lymphatic 
invasion, angioinvasion, perineural invasion, consistent with the 
more aggressive biology (10).
Previous attempts have been made to create a separate staging 
system for appendiceal tumors. Turaga et al. suggested creating 
a staging system for appendiceal tumors where subgroup A 
would include patients with carcinoid and carcinoma/mucinous 
carcinoma and subgroup B would included those with GCC and 
signet ring cell carcinoma. Notably, patients in subgroup B have 
a three times HR in comparison to all other stages (13). Tang 
et  al. classified appendiceal tumors with both neuroendocrine 
and glandular differentiation. Group A consisted of typical GCC, 
Group B was adenocarcinoma ex GCC, signet ring cell type, and 
Group C was adenocarcinoma ex GCC, poorly differentiated 
carcinoma type. According to the 2010 classification, Group B 
tumors are likely most consistent with MANEC tumors. Mean OS 
for Group B was 43 ± 6 months, which is shorter than our finding 
of 5.2 years. They also suggested that all patients in Group B and 
C should undergo right hemicolectomy as part of their manage-
ment (23). In future classification schemas, it appears prudent to 
include MANEC given its recognition by WHO and its biological 
behavior appearing more similar to signet ring than that of GCC 
or carcinoid.
There are several limitations associated with this study. 
Although this study represents the largest analysis of MANEC 
patients, it is retrospective in nature, which limits definitive 
conclusions being drawn to determine the optimal management 
of MANEC patients. Additionally, the SEER database is limited 
in the clinicopathological characteristics assessable to investigate 
deeper into those variables such as therapies (systemic and sur-
gical) associated with outcomes and survival. Additionally, the 
morphology was not reviewed by a single group of pathologists 
to ensure consistent use of terms.
Nonetheless, it appears evident from this population database 
and our institutional data that it is of utmost importance to 
distinguish MANEC from both GCC and carcinoid/neuroen-
docrine tumors given its more aggressive biology demonstrated. 
We recommend that patients with MANEC undergo aggressive 
multidisciplinary oncology management that may include sys-
temic therapy and well-selected aggressive surgical management. 
Future prospective studies are required to more conclusively 
define optimal management for MANEC patients.
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